News

‘AeroNabs’ Promise Powerful, Inhalable Protection Against COVID-19

Led by UCSF graduate student Michael Schoof, a team of researchers engineered a completely synthetic, production-ready molecule that straitjackets the crucial SARS-CoV-2 machinery that allows the virus to infect our cells.

Printerprezz and UCSF Enter Exclusive License Agreement

PrinterPrezz announced the exclusive, worldwide license of Spinal Interbody Device technology patent rights from the University of California, San Francisco. More

Exercise May Bolster the Brain

Exercise may help change exercisers’ brains in surprising ways, according to a new study of physical activity and brain health. The study, which included both mice and people, found that exercise prompts the liver to pump out a little-known protein, and that chemically upping the levels of that...

Relay Therapeutics Files for $200 Million IPO

Founded by UCSF Pharmaceutical Chemist Matt Jacobson, Relay Therapeutics filed for $200 Million IPO on June 25, 2020, and plans to list on the Nasdaq under the ticker RLAY, if accepted.

Sana Biotechnology Announces Completion of Initial Financing

Sonja Schrepfer's Sana Biotechnology, announced today the funding of all tranches of its initial financing, raising over $700 million.

Gilead Sciences to Acquire UCSF Startup Pionyr Immunotherapeutics

Gilead Sciences set to acquire a 49.9% equity interest in Pionyr and exclusive option for the price of $275 Million. Gilead will also provide funding for Pionyr’s clinical programs and will have the right to acquire the remainder of Pionyr shares for a $315 Million option exercise fee. Pionyr is...

FDA Approves Video Game Based on UCSF Brain Research as ADHD Therapy for Kids

The U.S. Food and Drug Administration has approved the first video game therapeutic as a treatment for attention deficit hyperactivity disorder (ADHD) in children, based on research by UC San Francisco’s Adam Gazzaley, MD, PhD. More

Recombinant Antibody Network Partners with Bristol Myers Squibb to Develop Novel Therapies

Recombinant Antibody Network (RAN) Partners with Bristol Myers Squibb to Develop Novel Therapies The Recombinant Antibody Network (RAN), a consortium comprising research groups from UC San Francisco, the University of Chicago, and the University of Toronto, has entered into a second research...

New COVID-19 Test Could Give Results in Under 1 Hour

New test, named SARS-CoV-2 DETECTR developed at UCSF. "The introduction and availability of CRISPR technology will accelerate deployment of the next generation of tests to diagnose COVID-19 infection," co-lead developer Dr. Charles Chiu said in a University of California, San Francisco news...

UCSF has Launched a World-wide Citizen Science Study to Help Fight COVID-19

Help fight COVID-19 in 5 minutes a day!